{"schema_version":"secwatch.filing_event.v1","accession":"0001657312-24-000011","form_type":"8-K","ticker":null,"cik":"0001657312","company_name":"Verona Pharma plc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.459938+00:00","generated_at":"2026-06-02T06:12:36.239537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verona Pharma reports Q1 net loss $25.8M; PDUFA for ensifentrine June 26, secures $650M financing","bullets":["Net loss $25.8M for Q1 2024 vs $16.7M in Q1 2023; SG&A costs rose to $20.4M on launch prep.","Cash and equivalents $254.9M at March 31, 2024; new $650M strategic financing available.","PDUFA target date for ensifentrine (COPD) is June 26, 2024; no advisory committee planned.","R&D expenses fell to $6.8M (Q1 2023: $12.6M) as ENHANCE Phase 3 program completed in 2023.","If approved, commercial launch in US expected Q3 2024; Phase 2 trials in COPD combo and bronchiectasis planned H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001657312-24-000011","json":"https://secwatch.observer/filing/0001657312-24-000011.json","markdown":"https://secwatch.observer/filing/0001657312-24-000011.md","text":"https://secwatch.observer/filing/0001657312-24-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/0001657312-24-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/vrna-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:12:36.239537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ead6abfb11e1de117fe2868e98cbab92f4f4fc39","claim":"Verona Pharma plc reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"Verona Pharma plc announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1657312/000165731224000011/0001657312-24-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}